QLT Inc. has dosed the first patient has been dosed in the Phase IIa proof-of-concept trial of QLT091001 in adult subjects with Impaired Dark Adaptation (IDA), a condition that results in decreased ability to recover visual sensitivity in the dark after exposure to bright lights.   The randomized, multi-center, parallel-group, placebo-controlled trial covers subjects (age 60 or older) with IDA, or impaired low luminance low contrast best corrected visual acuity (LLLC BCVA) in at least one ey...